Clearside Biomedical, Inc. Operating Income Loss

• Clearside Biomedical, Inc. showed a decrease of -16.3% in Operating Income Loss from 2023 to 2024.
• This data is from Clearside Biomedical, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2025.
• XBRL data for this metric is available from 2014 to 2024 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 11 years of available data (2014 to 2024), Clearside Biomedical, Inc.'s Operating Income Loss has declined by 194.0%.
• Historical annual values: Fiscal year 2024: -$28.88 million | Fiscal year 2023: -$24.84 million | Fiscal year 2022: -$30.28 million | Fiscal year 2021: -$627.0 thousand | Fiscal year 2020: -$17.94 million | Fiscal year 2019: -$30.30 million | Fiscal year 2018: -$82.95 million | Fiscal year 2017: -$58.41 million | Fiscal year 2016: -$25.20 million | Fiscal year 2015: -$17.32 million | Fiscal year 2014: -$9.82 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026